Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF32101 in R/R AML and MDS
NCT05703204Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLF32101 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum tolerated dose at 28 days and 3 more. Status: unknown.
02
Drugs
QLF32101
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05703204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703204.